Serpinb9 (Spi6)-deficient mice are impaired in dendritic cell-mediated antigen cross-presentation

Immunology and Cell Biology

Volumn 90, Issue 9, 2012, Pages 841-851

  Rizzitelli, Alexandra ^a,c   Meuter, Simone ^b,d   Vega Ramos, Javier ^b,d   Bird, Catherina H ^a   Mintern, Justine D ^b,e   Mangan, Matthew S J ^a   Villadangos, Jose ^b,d,e   Bird, Phillip I ^a  

^a MONASH UNIVERSITY   (Australia)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

cross presentation; dendritic cells; serpinb9

Indexed keywords

ANTIGEN; ENZYME INHIBITOR; SERPINB9; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BARE LYMPHOCYTE SYNDROME; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HELPER CELL; MOUSE; NONHUMAN; PROTEIN FUNCTION; PROTEIN SYNTHESIS;

ANIMALS; ANTIGEN PRESENTATION; CD8-POSITIVE T-LYMPHOCYTES; CELL SURVIVAL; CELLS, CULTURED; CROSS-PRIMING; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; GRANZYMES; H-2 ANTIGENS; IMMUNOBLOTTING; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MICROSCOPY, CONFOCAL; SERINE ENDOPEPTIDASES; SERPINS; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC;

ANIMALIA; MUS;

EID: 84867746580     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2012.29     Document Type: Article

References (39)

1. Pooley JL, Heath WR, Shortman K. Cutting edge: Intravenous soluble antigen is presented to CD4 T cells by CD8(-) dendritic cells, but cross-presented to CD8 T cells by CD8() dendritic cells. J Immunol 2001; 166: 5327-5330. (Pubitemid 32374150)
2. den Haan JM, Lehar SM, Bevan MJ. CD8() but not CD8(-) dendritic cells crossprime cytotoxic T cells in vivo. J Exp Med 2000; 192: 1685-1696.
3. Schnorrer P, Behrens GM, Wilson NS, Pooley JL, Smith CM, El-Sukkari D et al. The dominant role of CD8dendritic cells in cross-presentation is not dictated by antigen capture. Proc Natl Acad Sci USA 2006; 103: 10729-10734. (Pubitemid 44078044)
4. Bird PI, Trapani JA, Villadangos JA. Endolysosomal proteases and their inhibitors in immunity. Nat Rev Immunol 2009; 9: 871-882.
5. Amigorena S, Savina A. Intracellular mechanisms of antigen cross presentation in dendritic cells. Curr Opin Immunol 2010; 22: 109-117.
6. Shortman K, Heath WR. The CD8dendritic cell subset. Immunol Rev 2010; 234: 18-31.
7. Sun J, Bird CH, Sutton V, McDonald L, Coughlin PB, De Jong TA et al. A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine response modifier A is present in cytotoxic lymphocytes. J Biol Chem 1996; 271: 27802-27809. (Pubitemid 26367355)
8. Sun J, Ooms L, Bird CH, Sutton VR, Trapani JA, Bird PI. A new family of 10 murine ovalbumin serpins includes two homologs of proteinase inhibitor 8 and two homologs of the granzyme B inhibitor (proteinase inhibitor 9). J Biol Chem 1997; 272: 15434-15441. (Pubitemid 27255569)
9. Bird CH, Sutton VR, Sun J, Hirst CE, Novak A, Kumar S et al. Selective regulation of apoptosis: The cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathway. Mol Cell Biol 1998; 18: 6387-6398. (Pubitemid 28500528)
10. Bird CH, Blink EJ, Hirst CE, Buzza MS, Steele PM, Sun J et al. Nucleocytoplasmic distribution of the ovalbumin serpin PI-9 requires a nonconventional nuclear import pathway and the export factor Crm1. Mol Cell Biol 2001; 21: 5396-5407. (Pubitemid 32702444)
11. Hirst CE, Buzza MS, Bird CH, Warren HS, Cameron PU, Zhang M et al. The intracellular granzyme B inhibitor, proteinase inhibitor 9, is up-regulated during accessory cell maturation and effector cell degranulation, and its overexpression enhances CTL potency. J Immunol 2003; 170: 805-815. (Pubitemid 36070532)
12. Zhang M, Park SM, Wang Y, Shah R, Liu N, Murmann AE et al. Serine protease inhibitor 6 protects cytotoxic T cells from self-inflicted injury by ensuring the integrity of cytotoxic granules. Immunity 2006; 24: 451-461.
13. Ansari AW, Temblay JN, Alyahya SH, Ashton-Rickardt PG. Serine protease inhibitor 6 protects iNKT cells from self-inflicted damage. J Immunol 2010; 185: 877-883.
14. Medema JP, Schuurhuis DH, Rea D, van Tongeren J, de Jong J, Bres SA et al. Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: differential modulation by T helper type 1 and type 2 cells. J Exp Med 2001; 194: 657-667. (Pubitemid 32844775)
15. Andrew KA, Simkins HM, Witzel S, Perret R, Hudson J, Hermans IF et al. Dendritic cells treated with lipopolysaccharide up-regulate serine protease inhibitor 6 and remain sensitive to killing by cytotoxic T lymphocytes in vivo. J Immunol 2008; 181: 8356-8362.
16. Lovo E, Zhang M, Wang L, Ashton-Rickardt PG. Serine protease inhibitor 6 is required to protect dendritic cells from the kiss of death. J Immunol 2012; 188: 1057-1063.
17. Mangan MSJ, Melo-Silva CR, Luu J, Bind CH, Koskinen A, Rizzitelli A et al. Spi-6 is required to maintain the cellular immune response to ectromelia infection. (In preparation).
18. Hildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H, Kohyama M et al. Batf3 deficiency reveals a critical role for CD8alphadendritic cells in cytotoxic T cell immunity. Science 2008; 322: 1097-1100.
19. Iyoda T, Shimoyama S, Liu K, Omatsu Y, Akiyama Y, Maeda Y et al. The CD8dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J Exp Med 2002; 195: 1289-1302. (Pubitemid 34564331)
20. Li M, Davey GM, Sutherland RM, Kurts C, Lew AM, Hirst C et al. Cell-Associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo. J Immunol 2001; 166: 6099-6103. (Pubitemid 32440737)
21. Heusel JW, Wesselschmidt RL, Shresta S, Russell JH, Ley TJ. Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell 1994; 76: 977-987. (Pubitemid 24106379)
22. Rizzitelli A, Hawkins E, Todd H, Hodgkin PD, Shortman K. The proliferative response of CD4 T cells to steady-state CD8dendritic cells is restricted by post-Activation death. Int Immunol 2006; 18: 415-423. (Pubitemid 43329603)
23. Qiu CH, Miyake Y, Kaise H, Kitamura H, Ohara O, Tanaka M. Novel subset of CD8{alpha}dendritic cells localized in the marginal zone is responsible for tolerance to cell-Associated antigens. J Immunol 2009; 182: 4127-4136.
24. Sathe P, Pooley J, Vremec D, Mintern J, Jin JO, Wu L et al. The acquisition of antigen cross-presentation function by newly formed dendritic cells. J Immunol 2011; 186: 5184-5192.
25. Naik SH, Proietto AI, Wilson NS, Dakic A, Schnorrer P, Fuchsberger M et al. Cutting edge: Generation of splenic CD8and CD8-dendritic cell equivalents in Fms-like tyrosine kinase 3 ligand bone marrow cultures. J Immunol 2005; 174: 6592-6597. (Pubitemid 40705619)
26. Kamath AT, Henri S, Battye F, Tough DF, Shortman K. Developmental kinetics and lifespan of dendritic cells in mouse lymphoid organs. Blood 2002; 100: 1734-1741. (Pubitemid 34925152)
27. De Smedt T, Pajak B, Muraille E, Lespagnard L, Heinen E, De Baetselier P et al. Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J.Exp.Med 1996; 184: 1413-1424. (Pubitemid 26354697)
28. Savina A, Peres A, Cebrian I, Carmo N, Moita C, Hacohen N et al. The small GTPase Rac2 controls phagosomal alkalinization and antigen crosspresentation selectively in CD8() dendritic cells. Immunity 2009; 30: 544-555.
29. Kunz S, Sevilla N, McGavern DB, Campbell KP, Oldstone MB. Molecular analysis of the interaction of LCMV with its cellular receptor [alpha]-dystroglycan. J Cell Biol 2001; 155: 301-310. (Pubitemid 34289305)
30. Burgdorf S, Lukacs-Kornek V, Kurts C. The mannose receptor mediates uptake of soluble but not of cell-Associated antigen for cross-presentation. J Immunol 2006; 176: 6770-6776. (Pubitemid 43787859)
31. Kamphorst AO, Guermonprez P, Dudziak D, Nussenzweig MC. Route of antigen uptake differentially impacts presentation by dendritic cells and activated monocytes. J Immunol 2010; 185: 3426-3435.
32. Segura E, Albiston AL, Wicks IP, Chai SY, Villadangos JA. Different cross-presentation pathways in steady-state and inflammatory dendritic cells. Proc Natl Acad Sci USA 2009; 106: 20377-20381.
33. Kaiserman D, Bird CH, Sun J, Matthews A, Ung K, Whisstock JC et al. The major human and mouse granzymes are structurally and functionally divergent. J Cell Biol 2006; 175: 619-630. (Pubitemid 44790615)
34. Silverman GA, Bartuski AJ, Cataltepe S, Gornstein ER, Kamachi Y, Schick C et al. SCCA1 and SCCA2 are proteinase inhibitors that map to the serpin cluster at 18q21.3. Tumour Biol 1998; 19: 480-487. (Pubitemid 28539331)
35. Kessler JH, Khan S, Seifert U, Le Gall S, Chow KM, Paschen A et al. Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes. Nat Immunol 2011; 12: 45-53.
36. York IA, Mo AX, Lemerise K, Zeng W, Shen Y, Abraham CR et al. The cytosolic endopeptidase, thimet oligopeptidase, destroys antigenic peptides and limits the extent of MHC class I antigen presentation. Immunity 2003; 18: 429-440. (Pubitemid 36351521)
37. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell 1994; 76: 17-27. (Pubitemid 24035278)
38. Barnden MJ, Allison J, Heath WR, Carbone FR. Defective TCR expression in transgenic mice constructed using cDNA-based alpha-And beta-chain genes under the control of heterologous regulatory elements. Immunol Cell Biol 1998; 76: 34-40. (Pubitemid 28194695)
39. Vremec D, Pooley J, Hochrein H, Wu L, Shortman K. CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen. J Immunol 2000; 164: 2978-2986. (Pubitemid 30148956)